Eupraxia Pharmaceuticals Inc. (T:EPRX*CA)

Business Focus: Biotechnology & Medical Research (NEC)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
Company Contact
Address: 201-2067 Cadboro Bay Rd.
VICTORIA BC V8R 5G4
Tel: 1-416-4271235
Website: https://eupraxiapharma.com/home/default.aspx
IR: See website
<
Key People
Simon Pimstone
Non-Executive Independent Chairman of the Board
Bruce G. Cousins
President, Chief Financial Officer
James A. Helliwell
Chief Executive Officer, Director
Amanda Malone
Chief Scientific Officer
Paul A. Brennan
Chief Business Officer
 
Business Overview
Eupraxia Pharmaceuticals Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release alternatives to approved drugs. The Company's principal business is the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product candidate, EP-104IAR, is designed to meet the unmet medical need and market demand for long-lasting pain relief for knee osteoarthritis (OA). The primary active ingredient of the EP-104 products consists of a solid core of fluticasone propionate (FP) coated with an outer layer of polyvinyl alcohol (PVA). Its lead product candidate is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms and is used corticosteroid with systemic safety record. EP-104 is in Phase Ib/IIa clinical development.
Financial Overview
For the three months ended 31 March 2024, Eupraxia Pharmaceuticals Inc revenues was not reported. Net loss totaled to $6M. Results are not comparable due to currency change.
Employees: 29 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $128.86M as of Mar 31, 2024
Annual revenue (TTM): $0.00M as of Mar 31, 2024
EBITDA (TTM): -$41.11M as of Mar 31, 2024
Net annual income (TTM): -$41.82M as of Mar 31, 2024
Free cash flow (TTM): -$30.51M as of Mar 31, 2024
Net Debt Last Fiscal Year: N/A
Shares outstanding: 35,622,553 as of Mar 31, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.